What Is This Study About?
This 26-week study will assess the effects of three doses of moderate-intensity exercise in sedentary older adults who have age-related cognitive changes but no dementia. Aerobic fitness, physical function, and cognition will be assessed at baseline and 26 weeks to examine the dose-response relationships. At 52 weeks, cognition will be reassessed to examine the durability of cognitive changes.
Do I Qualify To Participate in This Study?
- Underactive or sedentary, based on the Telephone Assessment of Physical Activity
- Community dwelling, with a caregiver willing to accompany the participant to clinic visits; caregiver must visit with the subject more than five times a week
- Nondemented: Clinical Dementia Rating = 0
- Adequate seeing and hearing abilities to perform all aspects of the cognitive and functional assessments
- Stable doses of medications for at least 30 days prior to screening are allowed
Must NOT have:
- Dementia: Clinical Dementia Rating > 0
- Current major psychiatric disorder; significant psychiatric symptoms (e.g., hallucinations) that could impair completion of the study
- Current clinically significant systemic illness or infection likely to result in deterioration of the participant's condition or safety during the study
- History of clinically evident stroke; myocardial infarction or symptoms of coronary artery disease (e.g., angina) in the last 2 years; uncontrolled hypertension within the last 6 months
- History of cancer within the last 5 years (except nonmetastatic basal or squamous cell carcinoma)
- History of drug or alcohol abuse
- Insulin-dependent diabetes mellitus
- Significant pain or musculoskeletal disorder that would prohibit participation in an exercise program
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
University of Kansas Medical Center
Kansas City, 66160
Lead: Jeffrey Burns, MD
Source: ClinicalTrials.gov ID: NCT01129115